Home  |  Important Safety Information  |  Full Prescribing Information PDF  |  Contact Us  |  Site Map
Register for More Information  |  Send to a Friend
A
A
A
Print

Learn About Migraines

What are migraines that are long in duration and/or recur?

A migraine attack can last for 4 to 72 hours.1,20 The term long in duration means that migraine symptoms, such as pain, sensitivity to light, and aura, last for a long time. In one clinical study, it was documented that nearly two-thirds of patients had migraines that lasted up to 24 hours.20 The same study reported that one third of patients experienced migraines that lasted 24 to 72 hours.20

Migraines that recur are generally those that return within 24 hours of feeling relief from your symptoms.21,22 In one clinical study, a substantial number of patients — almost 44% — reported headache recurrence after initial relief.20

What are the signs and symptoms of migraines?

There are many common symptoms associated with migraine attacks with and without aura, including head pain and aching, light sensitivity, nausea, vomiting, visual changes, and sound sensitivity.1 Tracking the signs and symptoms of migraine is one way you can help your doctor to diagnose and stay involved in your migraine care.17

What is a menstrual migraine?

Migraines afflict approximately 21 million women in the United States — about 3 times more women than men.8 Studies have suggested that for many women, migraines may have something to do with changes in hormone levels that occur around the time of your period.14,15 This hormone-related migraine is often referred to as Menstrual Migraine.16 When compared with migraines that occur at other times of the month, Menstrual Migraine has been reported to be more severe,13 may last longer,11 and may recur more frequently.11

What to do next:

Learn more about migraines
Take the migraine quiz
Learn about FROVA®

The most common side effects associated with the use of FROVA are dizziness, tiredness, feeling of tingling, hot flashes, headache (other than migraine headache), dry mouth, hot or cold sensation, pain in joints or bones, chest pain, and indigestion.
+ View references
  1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia. 2004;24(suppl 1):24-36; 138-149. Available at: http://216.25.100.131/ihscommon/guidelines/pdfs/ihc_II_main_no_print.pdf. Accessed January 19, 2007.
  2. American Council for Headache Education. Headache diary. Available at: http://www.achenet.org/resources/diary.php. Accessed February 21, 2007.
  3. National Headache Foundation. Serotonin. Available at: http://www.headaches.org/consumer/topicsheets/serotonin.html. Accessed February 21, 2007.
  4. American Council for Headache Education. Women and headaches. Available at: http://www.achenet.org/news/women.php. Accessed February 21, 2007.
  5. American Council for Headache Education. Migraine and coexisting conditions. Available at: http://www.achenet.org/news/macc.php. Accessed February 21, 2007.
  6. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the Depo-Estradiol challenge test. Headache. 1996;36:367-371.
  7. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3:354-361.
  8. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
  9. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33:385-389.
  10. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
  11. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707-716.
  12. Couturier EGM, Bomhof MAM, Knuistingh Neven A, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308.
  13. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351-353.
  14. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45:1190-1201.
  15. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(72):2154-2158. doi: 10.1212/01.wnl.0000233888.18228.19.
  16. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
  17. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55:754-762.
  18. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Res Med Opin. 2004; 20(9):1465-1472. doi: 10.1185/030079904x2745.
  19. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
  20. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953. doi:10.1111/j.1526-4610.2006.00443.x.
  21. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780. doi:10.1111/j.1526-4610.2006.00437.x.
  22. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
  23. FROVA® Patient Product Information. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
     

    Important Safety Information

    For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.